Role of PPARand Its Agonist in Renal Diseases
Open Access
- 1 January 2010
- journal article
- review article
- Published by Wiley in PPAR Research
- Vol. 2010, 1-6
Abstract
Peroxisome proliferator-activated receptor (PPAR)-, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARactivation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARagonists may be good candidates for treating acute renal failure. In clinical application, PPAR-activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARin kidney diseases and the therapeutic utility of PPARmodulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-activators could provide important insights into the overall benefits of activating PPAR-clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.
Keywords
Funding Information
- Tzu Chi University (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
- Tzu Chi University (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
- Tzu Chi Hospital (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
- Tzu Chi Hospital (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
This publication has 44 references indexed in Scilit:
- Fibrates: no ACCORD on their use in the treatment of dyslipidaemiaCurrent Opinion in Lipidology, 2010
- PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activityBiochemical and Biophysical Research Communications, 2010
- Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathyExperimental Biology and Medicine, 2010
- SUMOylation of Human Peroxisome Proliferator-activated Receptor α Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoRJournal of Biological Chemistry, 2010
- Transgenic expression of proximal tubule peroxisome proliferator–activated receptor-α in mice confers protection during acute kidney injuryKidney International, 2009
- PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouseNephrology Dialysis Transplantation, 2006
- Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–α ActivatorsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Peroxisome Proliferator-Activated Receptor (PPAR) α and PPARβ/δ, but not PPARγ, Modulate the Expression of Genes Involved in Cardiac Lipid MetabolismCirculation Research, 2003
- Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activatorsThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and ratProceedings Of The Royal Society B-Biological Sciences, 1992